Yervoy delivers big survival benefit to patients; Nektar nabs $25M milestone from AstraZeneca;

@FierceBiotech: AstraZeneca CEO celebrates 1st anniversary with promising lung cancer data. More | Follow @FierceBiotech

@JohnCFierce: Pfizer nabs autoimmune disease drug rights for $25M upfront. News | Follow @JohnCFierce

@DamianFierce: Few are optimistic about a last-minute budget deal. Here's what happens at the FDA after a shutdown: Article | Follow @DamianFierce

> When it launched in March 2011, Bristol-Myers' ($BMY) Yervoy became the only drug ever to extend survival in patients with advanced forms of melanoma. Now, new data show just how long the breakthrough drug can extend that survival: A few patients using Yervoy could tack on as much as a decade to their lives, according to a long-term study. And more than a few could see a few extra years. Story

> The EMA has accepted AstraZeneca's ($AZN) application for naloxegol, triggering a $25 million milestone payday for Nektar Therapeutics. A nod from the FDA next would be worth another $70 million. Report

> Ariad Pharmaceuticals ($ARIA) presented updated Phase I/II data on its TKI drug AR26113 for non-small cell lung cancer. Release

Pharma News

@FiercePharma: Trending on our website (still): If reps can't get in doctors' front doors, try alternate routes. Story | Follow @FiercePharma

@EricPFierce: U.K. tosses lean, but important bone to with expected extension of cancer drug fund. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds. Story  | Follow @CarlyHFierce

> Germany's Bayer taps Pfizer's Olivier Brandicourt to head Bayer HealthCare. News

> Look out, pharma marketers. Obamacare will change your lives. More

> Roche CEO: 'Extremely' open to talk with Novartis about teaming up. Article

Medical Device News

@FierceMedDev: | Follow @FierceMedDev

@MarkHFierce: KKR made it official, grabbing an 80% stake of Panasonic's healthcare arm for $1.67B - much higher than predicted. ICYMI Friday | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Medtronic lands U.S. approval of early-generation artificial pancreas. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Intersect plugs positive drug-eluting sinus implant data. Item

> Life Tech to peddle Advanced Cell Diagnostics' RNA biomarker tech around the world. More

> KCI absorbs two acquisitions into wound care mega-company. Article

CRO News

> Quintiles jumps into personalized medicine for cancer trials. More

> Merged at last, PRA and RPS say they're fourth-largest CRO. Report

> InVentiv launches doc network for late-stage trials. Story

> JSS snaps up Latin American CRO. Article

> Parexel launches China-focused service as local demand heats up. News

Biotech IT News

> FDA taking hands-off approach to regulation of most apps. More

> Genohub talks up 'Kayak' for NGS services. Report

> NIH calls for comments on draft genomics data sharing policy. Story

> Business behind Google Earth for the human body raises $4M. Item

> Pfizer to give patients access to their trial data. Article

And Finally... Want to help protect your children from allergies and hypersensitivities? Raise them on a farm. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.